Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8 (+) selected tumor infiltrating lymphocytes from primary …
RA Figlin, WC Pierce, R Kaboo, CL Tso… - The Journal of …, 1997 - Elsevier
PURPOSE: Metastatic renal cell carcinoma is a disease with a mean survival of 6 to 10
months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is
associated with a 14% response rate and durable remissions in some patients with high
performance status. We performed a series of trials of IL-2 plus tumor infiltrating lymphocyte
cell therapy and report the clinical results from 62 patients enrolled in these trials.
MATERIALS AND METHODS: Patients were eligible if they had metastatic renal cell …
months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is
associated with a 14% response rate and durable remissions in some patients with high
performance status. We performed a series of trials of IL-2 plus tumor infiltrating lymphocyte
cell therapy and report the clinical results from 62 patients enrolled in these trials.
MATERIALS AND METHODS: Patients were eligible if they had metastatic renal cell …